U.S. markets open in 7 hours 9 minutes
  • S&P Futures

    4,545.75
    +37.25 (+0.83%)
     
  • Dow Futures

    34,300.00
    +298.00 (+0.88%)
     
  • Nasdaq Futures

    15,967.00
    +97.25 (+0.61%)
     
  • Russell 2000 Futures

    2,174.20
    +27.90 (+1.30%)
     
  • Crude Oil

    66.97
    +1.40 (+2.14%)
     
  • Gold

    1,778.30
    -6.00 (-0.34%)
     
  • Silver

    22.44
    +0.11 (+0.47%)
     
  • EUR/USD

    1.1319
    -0.0004 (-0.03%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    31.12
    +3.93 (+14.45%)
     
  • GBP/USD

    1.3297
    +0.0020 (+0.15%)
     
  • USD/JPY

    113.2200
    +0.4400 (+0.39%)
     
  • BTC-USD

    56,848.87
    -449.91 (-0.79%)
     
  • CMC Crypto 200

    1,443.05
    -26.03 (-1.77%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 3, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:

Wednesday, November 3, 2021

Time:

8:30 AM Eastern Time

Domestic:

877-407-0789

International:

201-689-8562

Conference ID:

13723637

Webcast:

http://public.viavid.com/index.php?id=146730

ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

© 2021 BioDelivery Sciences International, Inc. All rights reserved.

Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com